Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Léa Hoisnard, Laura Pina Vegas, Rosemary Dray‐Spira, Alain Weill, Mahmoud Zureik, É. Sbidian
Topics & Concepts
MedicineAdalimumabRheumatoid arthritisInternal medicineHazard ratioCohortPopulationProportional hazards modelTofacitinibCohort studyMaceSurgeryMyocardial infarctionConfidence intervalPercutaneous coronary interventionEnvironmental healthRheumatoid Arthritis Research and TherapiesSystemic Sclerosis and Related DiseasesVenous Thromboembolism Diagnosis and Management